Announcement – New Cancer Center Opening at 8613 Lee Highway, Fairfax, Virginia, 22031: The Fairfax office previously located at 8503 Arlington Blvd, Suite 400, has RELOCATED as of April 13th 2021. (Entrance is around on the side – the side not facing Lee Highway) – see here

COVID19 Update: All VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine are available for routine office visits. More Information-PLEASE CLICK HERE

Clinical Trial: 19054

Trial Status: Open
Disease Type: Breast
Trial ID 19054
Sponsor ID

Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Principal Investigator
Christina Brzezniak, DO
5 Locations

Locations

Fairfax Office

Alexandria Office

Arlington Office

Gainesville Office

Loudoun Office

Learn More About This Trial
Other Relevant Trials
Trial ID 20284
Sponsor ID Seattle Genetics, Inc.

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-025)

Principal Investigator
Anne Favret, MD
1 Location
Trial ID 19049
Sponsor ID Genentech, Inc.

The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a drug that looks like the study drug but contains no medication.) The usual chemotherapy in this…

Principal Investigator
Anne Favret, MD
5 Locations